| Literature DB >> 21102590 |
L B Zablotska1, E Ron, A V Rozhko, M Hatch, O N Polyanskaya, A V Brenner, J Lubin, G N Romanov, R J McConnell, P O'Kane, V V Evseenko, V V Drozdovitch, N Luckyanov, V F Minenko, A Bouville, V B Masyakin.
Abstract
BACKGROUND: Previous studies showed an increased risk of thyroid cancer among children and adolescents exposed to radioactive iodines released after the Chornobyl (Chernobyl) accident, but the effects of screening, iodine deficiency, age at exposure and other factors on the dose-response are poorly understood.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21102590 PMCID: PMC3039791 DOI: 10.1038/sj.bjc.6605967
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Descriptive characteristics of prevalent thyroid cases and non-cases
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| Gender | Men | 37 | 42.53 | 5602 | 48.61 | 1 | 0.12 | |
| Women | 50 | 57.47 | 5922 | 51.40 | 1.40 | 0.91–2.15 | ||
| Age at screening, years | 10–14 | 13 | 14.90 | 1379 | 12.00 | 1 | 0.19 | |
| 15–17 | 14 | 16.10 | 2161 | 18.80 | 0.89 | 0.41–1.91 | ||
| 18–20 | 12 | 13.80 | 2010 | 17.40 | 1.03 | 0.46–2.32 | ||
| 21–23 | 8 | 9.20 | 1891 | 16.40 | 0.71 | 0.29–1.75 | ||
| 24–26 | 19 | 21.80 | 1840 | 16.00 | 1.75 | 0.83–3.67 | ||
| 27–29 | 15 | 17.20 | 1533 | 13.30 | 1.73 | 0.79–3.79 | ||
| 30–34 | 6 | 6.90 | 708 | 6.10 | 1.61 | 0.59–4.43 | ||
| History of nodular goiter | No | 55 | 63.20 | 11 297 | 98.00 | 1 | <0.001 | |
| Yes | 32 | 36.80 | 227 | 2.00 | 23.21 | 14.34–37.57 | ||
| History of diffuse goiter | No | 78 | 89.70 | 11 277 | 97.90 | 1 | <0.001 | |
| Yes | 9 | 10.30 | 247 | 2.10 | 5.15 | 2.49–10.67 | ||
| Nodular goiter diagnosed during screening | No | 39 | 44.83 | 10 895 | 94.54 | 1 | <0.001 | |
| Yes | 48 | 55.17 | 629 | 5.46 | 19.79 | 12.65–30.96 | ||
| Diffuse goiter diagnosed during screening | No | 54 | 62.07 | 9750 | 84.61 | 1 | <0.001 | |
| Yes | 33 | 37.93 | 1774 | 15.39 | 3.16 | 2.02–4.94 | ||
| Family history of nodular goiter | No | 67 | 77.01 | 10 649 | 92.40 | 1 | <0.001 | |
| Yes | 20 | 22.99 | 875 | 7.60 | 3.54 | 2.13–5.89 | ||
| Oblast of residence at screening | Minsk | 16 | 18.40 | 3147 | 27.30 | 1 | 0.54 | |
| Gomel | 61 | 70.10 | 7110 | 61.70 | 1.12 | 0.63–2.01 | ||
| Other | 10 | 3.50 | 1267 | 11.40 | 1.29 | 0.58–2.87 | ||
| Urban status | Urban | 39 | 44.83 | 7007 | 60.80 | 1 | ||
| Rural | 48 | 55.17 | 4517 | 39.20 | 1.44 | 0.91–2.29 | 0.12 | |
| Urinary iodine concentration, | 0–19 | 10 | 11.50 | 1266 | 11.00 | 0.79 | 0.38–1.63 | 0.47 |
| 20–49 | 19 | 21.80 | 2988 | 25.90 | 0.65 | 0.37–1.17 | ||
| 50–99 | 30 | 34.50 | 3236 | 28.10 | 1 | |||
| 100–299 | 25 | 28.70 | 3426 | 29.70 | 0.83 | 0.49–1.43 | ||
| 300+ | 3 | 3.40 | 455 | 3.90 | 0.75 | 0.23–2.48 | ||
| Unknown | 0 | 0.00 | 153 | 1.30 | ||||
Abbreviation: CI=confidence interval.
Model adjusted for thyroid dose, age at risk, gender and oblast of residence (Minsk, Gomel, Other).
P-value from the likelihood ratio test evaluating statistical significance of adding corresponding variables to the model.
Figure 1Distribution of thyroid doses in the cohort
Odds ratios and 95% CI by thyroid dose category
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 0–0.049 | 0.02 | 6 | 6.9 | 1985 | 17.2 | 1 | |
| 0.05–0.14 | 0.09 | 11 | 12.6 | 2554 | 22.2 | 1.42 | 0.51–3.98 |
| 0.15–0.29 | 0.22 | 13 | 14.9 | 2053 | 17.8 | 2.09 | 0.76–5.75 |
| 0.30–0.44 | 0.37 | 10 | 11.5 | 1281 | 11.1 | 2.59 | 0.90–7.47 |
| 0.45–0.64 | 0.54 | 10 | 11.5 | 1034 | 9.0 | 3.27 | 1.13–9.46 |
| 0.65–1.24 | 0.90 | 16 | 18.4 | 1421 | 12.3 | 3.95 | 1.46–10.69 |
| 1.25–2.24 | 1.64 | 10 | 11.5 | 686 | 6.0 | 5.27 | 1.80–15.46 |
| 2.25–4.99 | 3.18 | 9 | 10.3 | 392 | 3.4 | 8.70 | 2.85–26.55 |
| 5.00–32.80 | 8.84 | 2 | 2.3 | 118 | 1.0 | 6.75 | 1.26–36.22 |
Abbreviations: CI=confidence interval; Gy=gray.
Model adjusted for age at risk, gender and oblast of residence (Minsk, Gomel, Other).
P-value of the test of linear trend based on mean values for dose categories=<0.01.
Figure 2Categorical odds ratios and fitted dose–response lines
Risk models and interaction terms for prevalent thyroid cancers
|
|
|
|
|
|
|---|---|---|---|---|
| All subjects | 85 | 2.15 | 0.81–5.47 | |
|
| ||||
| Men | 36 | 5.89 | 1.36–52.72 | 0.08 |
| Women | 49 | 1.17 | 0.23–3.70 | |
|
| ||||
| 0–4 | 26 | 4.02 | 0.98–15.07 | 0.48 |
| 5–11 | 30 | 1.95 | 0.41–6.17 | |
| 12–18 | 29 | 1.40 | NE–4.95 | |
|
| ||||
| Minsk and other | 9 | 2.06 | <0–21.89 | 0.07 |
| Gomel | 76 | 2.51 | 0.99–5.98 | |
|
| ||||
| No | 77 | 1.91 | 0.67–4.97 | <0.01 |
| Yes | 8 | 14.50 | 4.44–39.03 | |
|
| ||||
| No | 52 | 1.44 | 0.41–4.04 | <0.001 |
| Yes | 33 | 7.83 | 3.50–17.49 | |
| 0–19 | 10 | 2.40 | 1.91–7.55 | 0.30 |
| 20–49 | 19 | 1.14 | NE–4.06 | |
| 50–99 | 29 | 3.05 | NE–7.82 | |
| 100+ | 27 | 2.17 | NE–6.05 | |
|
| ||||
| No | 71 | 1.74 | 0.56–4.68 | <0.01 |
| Yes | 14 | 9.10 | 3.18–22.43 | |
|
| ||||
| <10 mm | 44 | 1.35 | 0.22–5.26 | 0.30 |
| 10+ mm | 41 | 3.40 | 1.00–13.11 | |
Abbreviations: CI=confidence interval; EOR/Gy=excess odds ratio per gray; NE=not estimated.
Data restricted to subjects with doses <5 Gy.
Model adjusted for age at risk, gender and oblast of residence (Minsk, Gomel, Other).
P-value from the likelihood ratio test of homogeneity across categories.
Excluding 150 subjects with missing urinary iodine concentration.
Thyroid enlargement was defined as a thyroid volume >18 ml for women and >25 ml for men.
Models of EOR/Gy and interaction terms for pre-screening and a combined set of pre-screening and prevalent thyroid cancers
|
|
| |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| All subjects | 48 | 8.18 | 2.11–72.71 | 133 | 3.16 | 1.49–6.95 | ||
|
| ||||||||
| Men | 26 | 2.68 | NE–74.59 | 0.88 | 62 | 6.27 | 1.96–30.44 | 0.13 |
| Women | 22 | 9.09 | 1.55–103.30 | 71 | 2.06 | 0.75–5.31 | ||
|
| ||||||||
| 0–4 | 23 | 4.98 | 0.91–43.94 | 0.32 | 49 | 2.82 | 1.04–7.27 | 0.92 |
| 5–7 | 12 | 10.44 | 2.56–76.99 | 24 | 3.33 | 1.14–8.37 | ||
| 8–18 | 13 | 12.24 | 1.88–109.40 | 60 | 3.43 | 1.23–8.92 | ||
|
| ||||||||
| Minsk and other | 6 | 10.09 | 2.70–63.26 | 0.15 | 15 | 1.00 | NE–4.19 | 0.04 |
| Gomel | 42 | 3.41 | NE–35.40 | 118 | 3.93 | 1.85–8.65 | ||
Abbreviations: CI=confidence interval; EOR/Gy=excess odds ratio per gray; NE=not estimated.
Data restricted to subjects with doses <5 Gy.
Model adjusted for age at risk, gender and oblast of residence (Minsk, Gomel, Other).
P-value from the likelihood ratio test of homogeneity across categories.